Effects of Exenatide on Motor Function and the Brain

NCT03456687 · Completed

Last updated 2026-05-28

This clinical trial tests whether the drug Exenatide can affect brain changes and movement symptoms in people with Parkinson's disease.

Status Completed The study has finished.

Phase Phase 1 Checks safety and dosing in a small group.

Type Interventional (clinical trial)

Design open-label (no blinding) treatment study

Participants 5 people

Who can join Ages 40–77 · all sexes

Timeline Started 2018-06 · est. completion 2021-08

Where 1 site · United States

What this study is testing ClinicalTrials.gov NCT03456687 ↗

Description as written by the study sponsor.

The purpose of this research study is to investigate how the brain and motor behavior changes Parkinson's Disease (PD) over time in response to Exenatide. In previous clinical trials, PD patients have experienced symptomatic improvement on Exenatide and literature suggests it may help slow the progression of Parkinson's. Both will be evaluated in this study.

Treatments tested

Exenatide also known as Bydureon, Glucagon-like peptide-1 receptor agonist Drug

Exenatide will be administered through a subcutaneous injection once per week for the duration of the study (1 year).

Main thing measured	Change in free-water accumulation in the substantia nigra
Sponsor	University of Florida
Conditions studied	Parkinson's Disease
GLP-1 drugs	exenatide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT03456687 ↗